Skip to main content

Table 1 Clinical characteristics of the populations with PBMCs enrolled in the study

From: IFI16 is involved in HBV-associated acute-on-chronic liver failure inflammation

group NC CHB HBV-ACLF
case 16 31 13
sex(M/F) 12/4 25/6 12/1
age(years) 29.5(26-63) 36(21-61) 44(37-67)
ALT(U/L) 21.5(11-34) 50(11-217) 90(46-245)
AST(U/L) 22(12-34) 46(21-222) 117(58-158)
Tbil(umol/L) ND 12.6(4.0-119.9) 473.8(51.9-720)
INR ND 1.04(0.88-1.23) 2.87(2.01-4.68)
PTA(%) ND 94(72-128) 26(16-39)
Log10 (HBV DNA) ND 5.17(1.30-8.23) 3.25(1.51-8.19)
HBsAg-positive 0 31 13
HBsAb-positive 16 0 0
HBeAg-positive 0 13 3
HBeAb-positive 0 18 10
HBcA-bpositive 0 31 13
MELD score ND ND 28.2±1.22
  1. Data are shown as median and range
  2. ACLF, acute on chronic liver failure; CHB, chronic hepatitis B; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Tbil, total bilirubin;HBcAb, hepatitis B c antibody; HBeAb, hepatitis B e antibody; HBeAg, hepatitis B e antigen; HBsAb, hepatitis B s antibody; HBsAg,hepatitis B s antigen; HBV, hepatitis B virus; ND, not determined; NC,normal control; PTA, prothrombin time activity; MELD Model for end-stage liver disease